T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2226
Forrester Research
FORR
$220M
| $401K | ﹤0.01% |
13,784
+56
| +0.4% | +$1.67K |
|
2227
Relmada Therapeutics
RLMD
$507M
| $400K | ﹤0.01% |
162,436
-16,004
| -9% | -$44.2K |
|
|
SRG
2228
Seritage Growth Properties
SRG
$131M
| $400K | ﹤0.01% |
44,750
| – | – |
|
2229
Simulations Plus
SLP
$371M
| $399K | ﹤0.01% |
9,205
+993
| +12% | +$43.4K |
|
2230
ImmunityBio
IBRX
$8.2B
| $398K | ﹤0.01% |
142,540
-24,218
| -15% | -$68.5K |
|
|
INN
2231
Summit Hotel Properties
INN
$656M
| $398K | ﹤0.01% |
61,016
+1,067
| +2% | +$7.06K |
|
|
PACW
2232
DELISTED
PacWest Bancorp
PACW
| $396K | ﹤0.01% |
48,496
+12,915
| +36% | +$104K |
|
2233
MasterCraft Boat Holdings
MCFT
$600M
| $395K | ﹤0.01% |
12,865
+227
| +2% | +$6.55K |
|
|
MRSN
2234
DELISTED
Mersana Therapeutics
MRSN
| $394K | ﹤0.01% |
4,774
-81
| -2% | -$11.8K |
|
2235
Novavax
NVAX
$1.31B
| $394K | ﹤0.01% |
52,993
-4,838
| -8% | -$38K |
|
|
SHCR
2236
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
| $394K | ﹤0.01% |
225,102
+4,558
| +2% | +$7.15K |
|
|
QUOT
2237
DELISTED
Quotient Technology Inc
QUOT
| $392K | ﹤0.01% |
101,871
+575
| +0.6% | +$1.78K |
|
2238
Hayward Holdings
HAYW
$3.25B
| $391K | ﹤0.01% |
30,407
+6,631
| +28% | +$76.5K |
|
2239
Pulmonx
LUNG
$98.4M
| $391K | ﹤0.01% |
29,758
+2,963
| +11% | +$36.2K |
|
|
AAIC
2240
DELISTED
Arlington Asset Investment Corp.
AAIC
| $390K | ﹤0.01% |
84,100
-8,000
| -9% | -$26.1K |
|
2241
Camden National
CAC
$990M
| $388K | ﹤0.01% |
12,501
+955
| +8% | +$30.5K |
|
|
EHAB
2242
DELISTED
Enhabit
EHAB
| $388K | ﹤0.01% |
33,727
+5,022
| +17% | +$62.7K |
|
|
NPKI
2243
NPK International
NPKI
$1.19B
| $388K | ﹤0.01% |
74,186
+23,000
| +45% | +$95.3K |
|
|
CCF
2244
DELISTED
Chase Corporation
CCF
| $388K | ﹤0.01% |
3,200
+136
| +4% | +$15.6K |
|
2245
SkinHealth Systems
SKIN
$84.2M
| $385K | ﹤0.01% |
45,960
+1,389
| +3% | +$14.4K |
|
2246
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$27.3B
| $384K | ﹤0.01% |
800
| – | – |
|
2247
Revolve Group
RVLV
$1.69B
| $384K | ﹤0.01% |
23,402
+735
| +3% | +$13.7K |
|
2248
Global Industrial
GIC
$1.49B
| $383K | ﹤0.01% |
13,777
+83
| +0.6% | +$2.15K |
|
2249
Tactile Systems Technology
TCMD
$555M
| $383K | ﹤0.01% |
15,355
-1,820
| -11% | -$37.8K |
|
|
HPP
2250
Hudson Pacific Properties
HPP
$777M
| $382K | ﹤0.01% |
12,898
+3,176
| +33% | +$114K |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.